Back to Browse Journals » International Journal of Chronic Obstructive Pulmonary Disease » Volume 4

Clinical utility of varenicline for smokers with medical and psychiatric comorbidity

Authors Jon O Ebbert, Kirk D Wyatt, Ali Zirakzadeh, et al

Published Date November 2009 Volume 2009:4 Pages 421—430

DOI http://dx.doi.org/10.2147/COPD.S6300

Published 17 November 2009

Jon O Ebbert, Kirk D Wyatt, Ali Zirakzadeh, Michael V Burke, JT Hays

Mayo Clinic College of Medicine, Mayo Clinic, Rochester, MN, USA

Abstract: Chronic obstructive pulmonary disease (COPD) is a costly and deadly disease afflicting an estimated 210 million people and accounting for 5% of all global deaths. Exposure to cigarette smoke is the greatest risk factor for COPD in the developed world. Smoking cessation improves respiratory symptoms and lung function and reduces mortality among patients with COPD. Cigarette smokers with COPD and other co-morbid conditions such as cardiovascular disease and psychiatric illnesses should receive comprehensive tobacco treatment interventions incorporating efficacious pharmacotherapies. Varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, is the newest and most effective drug currently available to promote smoking cessation. In conjunction with behavioral interventions and clinical monitoring for potential side effects, varenicline offers great hope for reducing smoking-attributable death and disability.

Keywords: smoking cessation, chronic obstructive pulmonary disease, varenicline

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Other article by this author:

Varenicline for smoking cessation: efficacy, safety, and treatment recommendations

Jon O Ebbert, Kirk D Wyatt, J Taylor Hays, et al

Patient Preference and Adherence 2010, 4:355-362

Published Date: 13 September 2010

Readers of this article also read:

The effect of reminder systems on patients' adherence to treatment

Fenerty SD, West C, Davis SA, Kaplan SG, Feldman SR

Patient Preference and Adherence 2012, 6:127-135

Published Date: 10 February 2012

Evaluation of in-vitro antibiotic susceptibility of different morphological forms of Borrelia burgdorferi

Sapi E, Kaur N, Anyanwu S, Luecke DF, Datar A, Patel S, Rossi M, Stricker RB

Infection and Drug Resistance 2011, 4:97-113

Published Date: 3 May 2011

Lyme disease: the next decade

Raphael B Stricker, Lorraine Johnson

Infection and Drug Resistance 2011, 4:1-9

Published Date: 7 January 2011

Varenicline for smoking cessation: efficacy, safety, and treatment recommendations

Jon O Ebbert, Kirk D Wyatt, J Taylor Hays, et al

Patient Preference and Adherence 2010, 4:355-362

Published Date: 13 September 2010

Health literacy and health seeking behavior among older men in a middle-income nation

Paul A Bourne, Chloe Morris, Christopher AD Charles, et al

Patient Related Outcome Measures 2010, 1:39-49

Published Date: 26 May 2010

Chronic obstructive pulmonary disease as an independent risk factor for cardiovascular morbidity

Joseph Finkelstein, Eunme Cha, Steven M Scharf

International Journal of Chronic Obstructive Pulmonary Disease 2009, 4:337-349

Published Date: 4 September 2009

Improving outcomes in patients undergoing percutaneous coronary intervention: role of prasugrel

Zuzana Motovska, Petr Widimsky

Vascular Health and Risk Management 2009, 5:475-481

Published Date: 21 May 2009

Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors

Eduardo Pimenta, Suzanne Oparil

Vascular Health and Risk Management 2009, 5:453-463

Published Date: 19 May 2009

Eggshell membrane: A possible new natural therapeutic for joint and connective tissue disorders. Results from two open-label human clinical studies

Kevin J Ruff, Dale P DeVore, Michael D Leu, Mark A Robinson

Clinical Interventions in Aging 2009, 4:235-240

Published Date: 18 May 2009